晚期非小细胞肺癌中切除修复交叉互补基因1的表达及临床意义

Expression of ERCC1 in Hunman Non-Small Cell Lung Cancer and Its Clinical Significance

目的:探讨非小细胞肺癌组织中切除修复交叉互补基因1(ERCC1)表达水平与顺铂化疗耐药及预后的相关性。方法:应用免疫组化链霉素抗生物素蛋白-过氧化物酶连接(SP)法检测104例非小细胞肺癌组织中ERCC1的表达并分析其与顺铂化疗耐药及1年生存率的关系。结果:非小细胞肺癌癌组织ERCC1表达水平与非小细胞肺癌患者性别及组织学类型无关,而与非小细胞肺癌患者以顺铂为基础联合化疗的耐药性有关。非小细胞肺癌化疗无效组ERCC1的阳性表达率为69.2%,明显高于化疗有效组12.8%,差异有统计学意义(P<0.05);ERCC1高表达者有较短的中位总生存期(11.0个月)和无进展生存(8.0个月),而ERCC1低表达患者有较长的中位总生存期(16.0个月)和无进展生存(13.0个月)。患者性别、年龄和组织类型与中位总生存期及无进展生存无相关性。结论:ERCC1在非小细胞肺癌组织中的表达水平与顺铂化疗耐药有关,ERCC1的高表达往往提示预后不佳。

Objective：To determine the relationship between the expression of （ERCC1） and cisplatin resistance in non-small cell lung cancer （NSCLC）. Methods：Useing the strep tavidin-peroxidase complex technique to examine the expression of ERCC1 in 104 non-small cell lung cancer tissues and to study relationship between the expression of ERCC1 and cisplatin resistance in non-small cell lung cancer（NSCLC）.Results：ERCC1 expression level did not show any association with patient age,sex,clinical stage and histology type. The expression of ERCC1 was associated with cisplatin resistance in non-small cell lung cancer. The positive expression rate of ERCC1 in chemoresistant group was 69.2%,that of chemosensitive one was 12.8%,it has significant difference between the two groups （P0.05）. Overexpression of ERCC1 protein was correlated with shorter median overall survival（11.0 months）and progression-free survival（8.0 months）.Lowexpression of ERCC1 protein was correlated with longer median overall survival（16.0 months）and progression-free survival（13.0 months）. Patient characteristics including age,gender,and histological subtype were not correlated with median overall survival or progression-free survival.Conclusions：The expression of ERCC1 in non-small cell lung cancer is related to cisplatin resistance,it shows predictive value to chemoresistance in non-small cell lung cancer.